Eli Lilly and Company (LLY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 25 | 28 | 29 | 34 | 45 | 65 | 80 | 89 |
| Operating profit | $bn | 30 | 40 | ||||||
| Net profit | $bn | 6 | 6 | 6 | 5 | 11 | 21 | 27 | 33 |
| EPS reported | $ | 22.95 | 29.80 | ||||||
| Operating cashflow per share | $ | 18.72 | 31.47 | ||||||
| Capex per share | $ | 8.73 | 9.00 | ||||||
| FCF per share | $ | 9.99 | 22.47 | ||||||
| Free cash flow | $bn | 9 | 20 | ||||||
| Net debt | $bn | 35 | 46 | ||||||
| Book value equity | $bn | 27 | 34 | ||||||
| Book value per share | $ | 29.55 | 37.91 | ||||||
| Number of shares | m | 898 | 893.7 | ||||||
| DPS (TTM paid) | $ | 6.00 | 6.69 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 46.83 | 39.71 | ||||||
| P/B LTM | x | 36.37 | 28.49 | ||||||
| P/S LTM | x | 14.81 | 12.11 | ||||||
| P/FCF LTM | x | 107.56 | 48.12 | ||||||
| EV/EBITDA LTM | x | 35.81 | 23.10 | ||||||
| EV/Sales LTM | x | 15.35 | 14.29 | ||||||
| Earnings Yield LTM | % | +2.14% | +2.52% | ||||||
| FCF Yield | % | +0.93% | +2.08% | ||||||
| Quality | |||||||||
| ROE | % | +77.78% | +92.58% | ||||||
| ROIC | % | +30.20% | +27.38% | ||||||
| Operating margin | % | +45.56% | +43.92% | ||||||
| Gross margin | % | +83.04% | +84.01% | ||||||
| FCF/Sales | % | +13.77% | +25.17% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +95.99% | +154.48% | ||||||
| Sales Growth YoY | % | +44.70% | +76.87% | ||||||
| Net Income Growth YoY | % | +94.88% | +152.23% | ||||||
| FCF Growth | % | +2065.6% | +4740.4% | ||||||
| Operating Profit Growth | % | +69.67% | +126.31% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.56% | +0.58% | ||||||
| Dividend Growth | % | +15.38% | +28.65% | ||||||
| Payout Ratio | % | +26.12% | +21.65% | ||||||
| FCF/Debt | x | 0.21 | 0.37 | ||||||
| Net Debt/EBITDA | x | 1.12 | 1.31 | ||||||
| EBIT/Net interest | x | 37.34 | 35.72 | ||||||
| Net debt/market cap | % | +4.40% | +5.03% | ||||||
| Net debt/Equity | x | 1.33 | 1.36 | ||||||
| Gross debt/equity | x | 1.60 | 1.62 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free